Risk of major adverse cardiovascular events, malignancy, thrombosis and death associated with use of Janus Kinase (JAK) inhibitors

The Health Sciences Authority (HSA), in consultation with its Product Vigilance Advisory Committee (PVAC), would like to update healthcare professionals on the outcome of its review on the risk of major adverse cardiovascular events (MACE), malignancy, thrombosis and death associated with the use of Janus Kinase (JAK) inhibitors for the treatment of inflammatory conditions. HSA's review concluded that the benefit-risk profile of JAK inhibitors remains positive for their approved indications, where the use of JAK inhibitors is already limited to second line or later therapy in Singapore. Healthcare professionals are advised to consider the benefits and risks of JAK inhibitors before prescribing the drugs, and to monitor their patients for these potential risks during treatment, particularly in patients with risk factors. Please refer to the letter for details.
Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

17 Nov 2022

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.